Work in progress: intra-arterial P-32 chromic phosphate for prevention of postoperative liver metastases in high-risk colorectal cancer patients.
Eight patients with locally extensive colorectal cancer were treated with colloidal P-32 chromic phosphate via the superior mesenteric artery following resection to prevent development of liver metastases. Less than 2% of the injected dose was found in the right atrial blood following the first pass through the liver and less than 1% in the urine. Therapy was tolerated well by all patients, with no acute complications. Long-term follow-up is needed to determine the effect of P-32 on the liver and the frequency of hepatic metastases.
D000230:Adenocarcinoma / Q000517:prevention & control* / Q000556:secondary / Q000601:surgery; D002857:Chromium / Q000008:administration & dosage / Q000627:therapeutic use*; D017608:Chromium Compounds; D003110:Colonic Neoplasms / Q000601:surgery; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000517:prevention & control*; D010710:Phosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000601:surgery; D012306:Risk
D017608:Chromium Compounds; D010710:Phosphates; D002857:Chromium; C509369:chromic phosphate